The most important question about a new lung cancer drug often comes before anyone writes a prescription: What, exactly, is driving this tumor? Two people with the same diagnosis may need very different medications because their cancers carry different genetic changes. The answer can also depend on whether the cancer is non-small cell or small cell, where it has spread, and what treatment the person has already received.
The need for better options remains urgent. Lung cancer caused an estimated 1.8 million deaths worldwide in 2022, making it the leading cause of cancer death that year. Yet treatment has changed substantially. Targeted drugs can interrupt a specific growth signal; immunotherapy can help immune cells attack cancer; and antibody-drug conjugates can carry a cancer-killing drug to cells with a particular marker.
Chemotherapy, surgery, and radiation still matter. In many cases, a newer medication works with one of those treatments, not instead of it. The useful question for patients and families isn’t simply which drug is newest. It’s which treatment has evidence for this cancer, at this stage, with these test results.
Targeted therapies: a shift toward precision
Targeted drugs act on a particular feature of the cancer, often a change in a gene that helps the tumor grow. For non-small cell lung cancer (NSCLC), testing may look for changes involving EGFR, ALK, ROS1, BRAF, MET, RET, KRAS, and HER2, among others. The exact change matters: an EGFR exon 20 insertion, for example, is not treated as though it were one of the more common EGFR mutations.
Osimertinib (Tagrisso) remains an important option for NSCLC with certain EGFR mutations. It can be used in eligible people with advanced cancer, after surgery to lower the risk of recurrence, or after chemoradiation for certain unresectable stage III cancers. Alectinib (Alecensa), an ALK inhibitor used for advanced ALK-positive NSCLC, is also approved after surgery for eligible ALK-positive tumors. These uses show why biomarker testing can matter even when a tumor appears removable.
The list of treatable alterations keeps growing. Sotorasib (Lumakras) is an option after prior systemic treatment for advanced NSCLC with a KRAS G12C mutation. For an EGFR exon 20 insertion, sunvozertinib (Zegfrovy) received accelerated FDA approval in 2025 for disease that progressed on or after platinum-based chemotherapy. Another drug, amivantamab (Rybrevant), has uses in EGFR-mutated NSCLC that depend on the specific mutation and treatment setting.
HER2-mutated lung cancer now has additional oral options. The FDA expanded approval of zongertinib (Hernexeos) to include previously untreated eligible patients in February 2026. In September 2026, it likewise expanded accelerated approval of sevabertinib (Hyrnuo) to eligible patients who had not yet received systemic therapy for advanced disease. Both approvals concern non-squamous NSCLC with particular HER2 gene mutations—not every tumor described as “HER2-positive.”
Many targeted drugs are pills, but “targeted” doesn’t mean gentle. Diarrhea, rash, liver problems, and, with some drugs, serious lung inflammation can occur. Cancer can also develop resistance. If a drug stops working, another biopsy or blood-based tumor test may reveal a change that helps guide the next choice.
Immunotherapy: helping immune cells respond
Immune checkpoint inhibitors block signals that cancer can use to restrain immune cells. Pembrolizumab (Keytruda), nivolumab (Opdivo), and atezolizumab (Tecentriq) are familiar examples, but they are not interchangeable across every lung cancer diagnosis.
For metastatic NSCLC without certain actionable driver alterations, pembrolizumab may be used alone in eligible patients whose tumors express PD-L1, or with chemotherapy in appropriate settings. The KEYNOTE-024 trial helped establish a survival benefit for pembrolizumab over chemotherapy in a group with high PD-L1 expression. PD-L1 is useful information, but it is not a promise that immunotherapy will work—and a lower result does not automatically rule out an immunotherapy-containing combination.
Checkpoint inhibitors also have roles around surgery and after chemoradiation for selected patients. In extensive-stage small cell lung cancer (SCLC), atezolizumab or durvalumab may be given with platinum-based chemotherapy and etoposide as initial treatment. These decisions depend on the cancer’s subtype and stage; a drug effective in NSCLC should not be assumed to work the same way in SCLC.
Side effects need a different kind of watchfulness from those of chemotherapy. Checkpoint inhibitors can cause the immune system to inflame healthy organs, including the lungs and liver. A new cough, shortness of breath, or other concerning symptom during treatment deserves prompt attention, even if earlier doses caused little trouble.
Small cell lung cancer has gained another kind of immune treatment. Tarlatamab (Imdelltra) is a bispecific antibody: it connects an immune cell to a small cell lung cancer cell. In November 2025, the FDA granted traditional approval for extensive-stage SCLC that progressed on or after platinum-based chemotherapy. In the trial supporting that decision, median overall survival was 13.6 months with tarlatamab versus 8.3 months with the chemotherapy options studied. It requires careful monitoring because it can cause serious immune reactions and neurologic side effects.
Antibody-drug conjugates: targeted delivery with real risks
An antibody-drug conjugate, or ADC, joins an antibody to a potent cancer-killing drug. The antibody helps direct treatment toward cells carrying its target. That design does not spare every healthy cell, so ADCs should not be understood as chemotherapy without side effects.
Fam-trastuzumab deruxtecan (Enhertu) is an ADC for eligible people with unresectable or metastatic NSCLC carrying an activating HER2 mutation after prior systemic therapy. HER2 mutation and HER2 protein overexpression are different test findings; patients need to know which one their report identifies. Enhertu can cause serious lung inflammation, making a new cough or worsening breathing especially important to report.
Another ADC, telisotuzumab vedotin (Emrelis), received accelerated approval for certain previously treated, non-squamous NSCLC tumors with high c-Met protein overexpression. That is not the same finding as a MET exon 14-skipping mutation, which can qualify a patient for a different targeted approach.
“Accelerated approval” is still FDA approval, but it reflects an earlier decision based on a measure expected to predict patient benefit, such as tumor shrinkage. Follow-up studies are required to confirm clinical benefit. That distinction matters when comparing a newly approved drug with a treatment backed by longer-term survival data.
Emerging therapies under investigation
Cancer vaccines and tumor-infiltrating lymphocyte (TIL) therapy remain areas of lung cancer research. TIL therapy involves collecting immune cells from a tumor, growing them outside the body, and giving them back to the patient as part of a treatment regimen. These approaches should not be confused with established lung cancer medications: their value and safety in this disease are still being tested.
Clinical trials may also examine new drug combinations or treatments matched to uncommon tumor alterations. The NCI’s Lung-MAP study, for example, screens tumors from people with advanced NSCLC that has continued to grow after treatment and studies different treatments for different findings. A trial is worth discussing when standard options are limited, but eligibility, travel, possible benefit, and risks all need a close look.
A direct comparison of medication categories
| Treatment category | Examples | Main selection factor | Important limitation |
|---|---|---|---|
| Targeted therapy | Osimertinib, alectinib, sotorasib | A matching tumor alteration and the right stage or prior-treatment history | A drug for one mutation may not work for another; resistance can develop |
| Checkpoint immunotherapy | Pembrolizumab, nivolumab, atezolizumab | Cancer subtype, stage, biomarkers, and planned combination | Benefit varies; immune-related organ inflammation can be serious |
| Antibody-drug conjugates | Enhertu, Emrelis | The specific HER2 mutation or c-Met protein test result required for the drug | Can cause substantial toxicity despite targeted delivery |
| Chemotherapy | Carboplatin with another drug such as paclitaxel or etoposide | Cancer subtype and treatment setting | Affects healthy as well as cancer cells; often remains part of the most effective regimen |
The table is a starting point, not a ranking. In particular, chemotherapy is not merely a fallback when newer drugs are unavailable. It may be part of first-line treatment or combined with immunotherapy.
Securing medication and building a care strategy
For someone newly diagnosed with NSCLC, the most useful early question is whether there is enough tumor tissue for appropriate biomarker testing, including molecular testing and PD-L1 testing when relevant. The National Cancer Institute notes that biomarker testing is routinely used to select treatment for NSCLC. Results may affect the first treatment chosen, so patients can ask whether treatment should wait for pending results when it is medically safe to do so.
Bring the full pathology and molecular reports to the treatment discussion, not just a statement that testing was “positive.” Ask which finding supports the recommended drug, what outcome the treatment is meant to improve, what side effects require an urgent call, and which options remain if it does not work.
Access is part of that plan. Insurance authorization, specialty pharmacies, infusion visits, and travel can delay care or create large out-of-pocket costs. A cancer center’s financial counselor or navigator can help patients understand coverage and expected expenses before treatment starts.
Continuing oversight and treatment changes
Lung cancer treatment is reassessed, not set once and left alone. Imaging shows whether a tumor is shrinking or growing; visits and blood tests help the team spot side effects. A scan result also has to be read alongside symptoms and the overall treatment goal. A drug that is controlling cancer may need a dose change or a pause because of toxicity, while growth after a targeted drug may call for new tumor testing.
The progress is real, but its value lies in matching treatment to the person and the tumor. Knowing the cancer subtype, stage, exact biomarker results, and prior treatments turns a long list of “breakthrough” drugs into a smaller set of choices that can be discussed clearly with an oncology team.
Disclaimer
This article provides general health information and is not a substitute for advice from a qualified cancer care professional.